220 related articles for article (PubMed ID: 28031572)
1. Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.
Crunkhorn S
Nat Rev Drug Discov; 2016 Dec; 16(1):18. PubMed ID: 28031572
[No Abstract] [Full Text] [Related]
2. [BACE1 inhibitors for the treatment of Alzheimer disease].
Tomita T
Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
[TBL] [Abstract][Full Text] [Related]
3. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
4. [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Shitaka Y; Mitani Y; Nagakura A; Miyake A; Matsuoka N
Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):15-20. PubMed ID: 20628208
[No Abstract] [Full Text] [Related]
5. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
7. The evolution of amidine-based brain penetrant BACE1 inhibitors.
Oehlrich D; Prokopcova H; Gijsen HJ
Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
[TBL] [Abstract][Full Text] [Related]
8. Introduction to special issue on Alzheimer's disease.
Wolfe MS
J Med Chem; 2012 Nov; 55(21):8977-8. PubMed ID: 23039833
[No Abstract] [Full Text] [Related]
9. Synthesis and evaluation of arylquinones as BACE1 inhibitors, β-amyloid peptide aggregation inhibitors, and destabilizers of preformed β-amyloid fibrils.
Ortega A; Rincón Á; Jiménez-Aliaga KL; Bermejo-Bescós P; Martín-Aragón S; Molina MT; Csákÿ AG
Bioorg Med Chem Lett; 2011 Apr; 21(8):2183-7. PubMed ID: 21441028
[TBL] [Abstract][Full Text] [Related]
10. Bad news and good news in AD, and how to reconcile them.
Knopman DS
Nat Rev Neurol; 2019 Feb; 15(2):61-62. PubMed ID: 30622292
[No Abstract] [Full Text] [Related]
11. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
Jeppsson F; Eketjäll S; Janson J; Karlström S; Gustavsson S; Olsson LL; Radesäter AC; Ploeger B; Cebers G; Kolmodin K; Swahn BM; von Berg S; Bueters T; Fälting J
J Biol Chem; 2012 Nov; 287(49):41245-57. PubMed ID: 23048024
[TBL] [Abstract][Full Text] [Related]
12. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
13. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
14. [BACE1 and glycosyltransferases].
Kitazume-Kawaguchi S; Hashimoto Y; Saido T
Tanpakushitsu Kakusan Koso; 2003 Jun; 48(8 Suppl):984-9. PubMed ID: 12806999
[No Abstract] [Full Text] [Related]
15. BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
Sakamoto K; Matsuki S; Matsuguma K; Yoshihara T; Uchida N; Azuma F; Russell M; Hughes G; Haeberlein SB; Alexander RC; Eketjäll S; Kugler AR
J Clin Pharmacol; 2017 Nov; 57(11):1460-1471. PubMed ID: 28618005
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells.
Chen LM; Lin ZY; Zhu YG; Lin N; Zhang J; Pan XD; Chen XC
Eur J Pharmacol; 2012 Jan; 675(1-3):15-21. PubMed ID: 22166376
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease research: the future of BACE inhibitors.
Burki T
Lancet; 2018 Jun; 391(10139):2486. PubMed ID: 29976459
[No Abstract] [Full Text] [Related]
18. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW
Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835
[TBL] [Abstract][Full Text] [Related]
19. Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
Wu YJ; Guernon J; Rajamani R; Toyn JH; Ahlijanian MK; Albright CF; Muckelbauer J; Chang C; Camac D; Macor JE; Thompson LA
Bioorg Med Chem Lett; 2016 Dec; 26(23):5729-5731. PubMed ID: 27816517
[TBL] [Abstract][Full Text] [Related]
20. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
May PC; Willis BA; Lowe SL; Dean RA; Monk SA; Cocke PJ; Audia JE; Boggs LN; Borders AR; Brier RA; Calligaro DO; Day TA; Ereshefsky L; Erickson JA; Gevorkyan H; Gonzales CR; James DE; Jhee SS; Komjathy SF; Li L; Lindstrom TD; Mathes BM; Martényi F; Sheehan SM; Stout SL; Timm DE; Vaught GM; Watson BM; Winneroski LL; Yang Z; Mergott DJ
J Neurosci; 2015 Jan; 35(3):1199-210. PubMed ID: 25609634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
